NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis $52.95 0.00 (0.00%) As of 05/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Terns Pharmaceuticals Stock (NASDAQ:TERN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Terns Pharmaceuticals alerts:Sign Up Key Stats Today's Range$52.94▼$52.9850-Day Range$41.51▼$53.1752-Week Range$2.65▼$53.19Volume6.35 million shsAverage Volume4.84 million shsMarket Capitalization$6.12 billionP/E RatioN/ADividend YieldN/APrice Target$55.14Consensus RatingHold Company Overview Terns Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies. The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation. These include inhibitors of key pathways implicated in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as programs directed at hepatocellular carcinoma. Each candidate is being investigated for its ability to modulate disease drivers such as bile acid metabolism, immune cell activation and cell‐signaling cascades involved in fibrosis. Terns leverages state‐of‐the‐art medicinal chemistry and translational biology platforms to optimize both efficacy and safety profiles across its portfolio. Headquartered in San Diego, California, Terns Pharmaceuticals operates in a hub known for innovation in hepatology and liver disease research. The company’s management and scientific leadership bring extensive experience from established biotech and pharmaceutical organizations, with deep expertise in clinical development, regulatory strategy and commercialization planning. By combining this leadership team’s industry knowledge with strategic partnerships and academic collaborations, Terns is positioned to advance its therapeutic candidates toward regulatory milestones and, ultimately, broaden treatment options for patients suffering from severe liver diseases.AI Generated. May Contain Errors. Read More Terns Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreTERN MarketRank™: Terns Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 639th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingHold Consensus RatingTerns Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 1 strong buy rating, 3 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Terns Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTerns Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Terns Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 5.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.87% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 31.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.77 News SentimentTerns Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,302,370.00 in company stock.Percentage Held by Insiders1.50% of the stock of Terns Pharmaceuticals is held by insiders.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TERN Stock News HeadlinesMerck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5, 2026 | businesswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from BrokeragesMay 5, 2026 | americanbankingnews.comThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requires more electricity than some small countries use in a year, and SEC rules require it be disclosed. When that figure goes public, every analyst on Wall Street will race to identify the supplier. One small company already has a $1.5 billion backlog - and Dylan Jovine has the name and ticker. | Behind the Markets (Ad)Merck still sees ‘compelling’ outlook for Terns leukemia drugApril 30, 2026 | finance.yahoo.comOppenheimer downgrades Terns Pharmaceuticals (TERN)April 28, 2026 | msn.comTerns Pharmaceuticals gets FDA breakthrough status for leukemia drugApril 27, 2026 | investing.comTerns Pharmaceuticals Gets Breakthrough Designation for Leukemia TreatmentApril 27, 2026 | marketwatch.comTerns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaApril 27, 2026 | globenewswire.comSee More Headlines TERN Stock Analysis - Frequently Asked Questions How have TERN shares performed this year? Terns Pharmaceuticals' stock was trading at $40.40 on January 1st, 2026. Since then, TERN shares have increased by 31.1% and is now trading at $52.95. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) issued its quarterly earnings results on Monday, March, 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $120 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Terns Pharmaceuticals' top institutional investors include Pictet Asset Management Holding SA (1.43%), Candriam S.C.A. (0.55%), Jennison Associates LLC (0.43%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Hongbo Lu, Amy L Burroughs, Vivo Opportunity, Llc, Emil Kuriakose, Mark J Vignola, Andrew Gengos, Melita Sun Jung and Jill M Quigley. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Terns Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings3/30/2026Today5/14/2026Next Earnings (Estimated)5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TERN's financial health is in the Green zone, according to TradeSmith. TERN has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TERN CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Terns Pharmaceuticals$55.14 High Price Target$70.00 Low Price Target$44.50 Potential Upside/Downside+4.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.02% Return on Assets-19.37% Debt Debt-to-Equity RatioN/A Current Ratio62.41 Quick Ratio62.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.70 per share Price / Book5.46Miscellaneous Outstanding Shares115,520,000Free Float113,788,000Market Cap$6.12 billion OptionableNot Optionable Beta-0.37 Social Links 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:TERN) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredSpaceX IPO Warning: Before you buy any SpaceX shares, read this.The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...Weiss Ratings | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMillionaire trader: “Buy this before May 15.”Hedge fund legend Larry Benedict - who beat the S&P 500 by 18 times in 2025 and generated $95 million for clie...Brownstone Research | SponsoredElon’s ‘iPhone’ Could 10x Apple’s iPhoneEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
